Who is sponsoring IG-TATRY?

IG-TATRY is sponsored by Shire.

What condition does IG-TATRY study?

IG-TATRY studies Primary Immunodeficiencies (PID).

What is the status of IG-TATRY?

IG-TATRY is currently COMPLETED.

Last reviewed 2021-11-17 · How we verify

Retrospective, Observational Chart Review Study Conducted in Poland to Document the Management and Clinical Outcome of CUVITRU and HYQVIA in Pediatric Participants (< 18 Years) With Primary Immunodeficiency (PID) (IG-TATRY)

NCT04636502 COMPLETED

The purpose of this observational, multi-center, retrospective cohort study is to assess treatment patterns of Cuvitru (SCIG) 20 percent (%) and HyQvia (fSCIG) in polish pediatric participants with PID. The study will collect pediatric patient data. These data are gathered and collected during routine clinical care. As this is a non-interventional/observational study, no treatment/pharmacotherapy is provided as part of the study.

Details

Lead sponsor	Shire
Status	COMPLETED
Enrolment	96
Start date	Mon Feb 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Primary Immunodeficiencies (PID)

Countries

Poland